Our Blog
-
BioUtah Letter on Prioritizing Life Sciences Workers for Vaccine Distribution
December 3, 2020 Mr. Rich Lakin, MSPH, MPA Immunizations Director Utah Department of Health Bureau of Epidemiology PO…
-
ProLung Has a New Name, Gets $3.3 Million Private Placement and More…
ProLung, now IONIQ Sciences (IONIQ), has been on a roll! Last week, the company announced that they had fully…
-
Co-Diagnostics Joint Venture, CoSara, Invited to Participate in 2nd Advanced TB Diagnostics Course in Chennai, India
Co-Diagnostics Joint Venture, CoSara, Invited to Participate in 2nd Advanced TB Diagnostics Course in Chennai, India
-
Owlet Announces New DME Partnership With 1 Natural Way to Expand Insurance-Supported Access to BabySat® Infant Pulse Oximeter
Collaboration expands Owlet’s national DME footprint, strengthens access for Medicaid and TRICARE families, and supports continued growth in…
-
CancerVax Reports Nanoparticle Component Success in Preparation for Animal Studies
In-vitro studies confirmed strong uptake of cell-targeting nanoparticles by cancer cells and strong activation of Smart mRNAs inside…
-
Peel Therapeutics CEO Joshua Schiffman Presents at CureCRC Summit
Peel Therapeutics CEO Joshua Schiffman Presents at CureCRC Summit
-
Ratio Therapeutics has Successfully Dosed the First Cohort in its Phase 1/2 Study Evaluating a Novel FAP-Targeted Radiopharmaceutical in Patients with Late-Stage Aggressive Sarcomas
Ratio Therapeutics has Successfully Dosed the First Cohort in its Phase 1/2 Study Evaluating a Novel FAP-Targeted Radiopharmaceutical…
-
Investors Buy up Stocks in Biggest Follow-on Offering Day in Biotech History
Investors Buy up Stocks in Biggest Follow-on Offering Day in Biotech History
-
Talent Ready Utah Calling for Innovator Input
Talent Ready Utah Calling for Innovator Input
-
Owlet Launches TGA-Approved Dream Sock™ in Australia & New Zealand, Expanding International Footprint and Bringing Trusted Pediatric Health Monitoring to More Families Worldwide
TGA approval enables regional launch of Owlet’s clinically validated, award-winning infant health monitor; Owlet360™ subscription marks first international…
-
Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks
REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp…